Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).

TSXV:SBM - Post by User

Sirona Biochem Corp > Fins on sedar

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Feb 29, 2024 2:44pm

121 Views

Post# 35907238

RE:RE:RE:RE:RE:Fins on sedar

Mgmt also must have used q4 as a correction qtr instead of restating q1,q2,q3. My estimate.....

Qtr ending	Sales to Abbvie	R+F settlement	Other income	Total Revenue + Other income
Oct 23	27,964	0	3,852	31,816
Jul 23	6,815	0	16	6,831
Apr 23	0	59,514	1,388	60,902
Jan 23	0	0	1,467	1,467
Total	34,779	59,514	6,723	101,016

biorun wrote: The revenue was deemed by the auditors to be related to close out settlement with R&F, not from product sales (which would be reported on the revenue line), so the revenue is captured in "other income" lower down on the table.

<< Previous

Bullboard Posts

Next >>

Xplore Resources to expand position near Surge Lithium Project